NFL BIOSCIENCES (EPA:ALNFL)

REGULATED PRESS RELEASE

published on 01/30/2024 at 08:00, 10 months 23 days ago

NFL BIOSCIENCES : SUCCÈS DE L’ÉTUDE AVEC LE CEA
NFL BIOSCIENCES annonce la mise en ubrique, étude d'imagerie moléculaire menée par le CEA, du mécanisme d'action innovant du candidat médicament NFL-101 pour le sevrage tabagique

NFL Biosciences Étude D'imagerie Moléculaire Sevrage Tabagique CEA Mécanisme D'action
REGULATED PRESS RELEASE

published on 01/30/2024 at 08:00, 10 months 23 days ago

NFL BIOSCIENCES: SUCCESS OF THE STUDY WITH THE CEA
NFL BIOSCIENCES announces the successful study with the CEA demonstrating a new mechanism of action for smoking cessation using NFL-101, a botanical drug. Results open new possibilities for addiction treatment

NFL Biosciences Addiction Treatment CEA Study Smoking Cessation NFL-101
ARTICLE

published on 01/12/2024 at 18:16, 11 months 9 days ago

NFL Biosciences confirme son éligibilité au dispositif PEA-PME pour 2024
L'entreprise biopharmaceutique montpelliéraine NFL Biosciences confirme l'éligibilité de ses actions au dispositif PEA-PME, favorisant l'investissement dans les PME et ETI

PEA-PME NFL Biosciences Médicaments Botaniques Traitement Des Addictions Investissement Dans Les PME
REGULATED PRESS RELEASE

published on 01/12/2024 at 17:45, 11 months 9 days ago

NFL BIOSCIENCES CONFIRME SON ÉLIGIBILITÉ AU DISPOSITIF PEA-PME
NFL BIOSCIENCES confirme son éligibilité au dispositif PEA PME pour l'année 2024, permettant l'intégration de ses actions dans les portefeuilles PEA PME. Prochaine publication financière : Résultats annuels 2023, le 29 mars 2024, après Bourse

Euronext Growth Paris NFL Biosciences Médicaments Botaniques PEA PME Biopharmaceutique
REGULATED PRESS RELEASE

published on 01/09/2024 at 17:45, 11 months 12 days ago

NFL BIOSCIENCES : AGENDA DE COMMUNICATION FINANCIÈRE 2024
La société biopharmaceutique NFL BIOSCIENCES annonce son calendrier de communication financière pour l'année 2024, incluant les résultats annuels 2023 et d'autres événements importants

NFL Biosciences Médicaments Botaniques Communication Financière Résultats Annuels Biopharmaceutique
REGULATED PRESS RELEASE

published on 01/09/2024 at 17:45, 11 months 12 days ago

NFL BIOSCIENCES: FINANCIAL CALENDAR FOR 2024
NFL Biosciences, a biopharmaceutical company, has announced its financial communication calendar for 2024, including dates for annual results, Annual General Meeting, and half-year results. The company is known for developing botanical drug candidates for the treatment of addictions, such as NFL-101 for nicotine cessation and NFL-301 for reducing alcohol consumption. For more information, visit www.nflbiosciences.com.

NFL Biosciences Biopharmaceutical Company Financial Calendar 2024 Botanical Drug Candidates Addiction Treatment
REGULATED PRESS RELEASE

published on 01/08/2024 at 17:45, 11 months 13 days ago

NFL BIOSCIENCES : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ 2ème SEMESTRE 2023
ARTICLE

published on 12/19/2023 at 08:40, 1 year ago

NFL Biosciences engage le processus d'approbation de la FDA pour son traitement contre l'alcoolisme
NFL Biosciences vise à renforcer sa présence sur le marché pharmaceutique en proposant une nouvelle solution thérapeutique contre la dépendance à l'alcool

NFL Biosciences FDA Pre-IND Consommation Excessive D'alcool Traitement Des Dépendances
REGULATED PRESS RELEASE

published on 12/19/2023 at 08:00, 1 year ago

NFL BIOSCIENCES: PRE-IND APPLICATION FILED WITH THE FDA IN THE UNITED STATES FOR NFL-301, INDICATED FOR REDUCING ALCOHOL CONSUMPTION
REGULATED PRESS RELEASE

published on 12/19/2023 at 08:00, 1 year ago

NFL BIOSCIENCES : DÉPÔT D’UNE DEMANDE DE PRE-IND AUPRÈS DE LA FDA AUX ÉTATS-UNIS POUR NFL- 301 DÉDIÉ À LA RÉDUCTION DE LA CONSOMMATION D’ALCOOL

Published on 12/21/2024 at 01:30, 1 day 10 hours ago

Quantum Biopharma Announces Closing of Second Tranche
Published on 12/21/2024 at 01:30, 1 day 10 hours ago

iMetal Resources Closes First Tranche of Previously Announced Non-Brokered Private Placement
Published on 12/21/2024 at 00:05, 1 day 12 hours ago

Chloeta Awarded GSA OASIS+ IDIQ Contract for Intelligence, Federal Civilian and Defense Support Services
Published on 12/21/2024 at 00:00, 1 day 12 hours ago

Amarc Announces Loan Extension
Published on 12/20/2024 at 23:30, 1 day 12 hours ago

Boron One Announces Extension to Early Warrant Exercise Incentive Program

View all ACCESSWIRE

Published on 12/21/2024 at 00:51, 1 day 11 hours ago

Acquisition of PSI Transcom GmbH by CHAPTERS platform Altamount Software GmbH
Published on 12/21/2024 at 00:45, 1 day 11 hours ago

EQS-Adhoc: PSI sells the Mobility business unit
Published on 12/20/2024 at 19:10, 1 day 17 hours ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 12/20/2024 at 18:56, 1 day 17 hours ago

CPI PROPERTY GROUP – Progress on Key Initiatives
Published on 12/20/2024 at 18:00, 1 day 18 hours ago

ARYZTA AG Announces New Board Technology Committee

View all EQS

Published on 12/21/2024 at 12:17, 23 hours 55 minutes ago

AXA annonce la signature d’un accord relatif à la vente d'AXA Investment Managers à BNP Paribas
Published on 12/21/2024 at 12:17, 23 hours 55 minutes ago

AXA announces the signing of a share purchase agreement with BNP Paribas relating to the sale of AXA IM
Published on 12/20/2024 at 18:00, 1 day 18 hours ago

Kapitaalverhoging door uitoefening van inschrijvingsrechten
Published on 12/20/2024 at 18:00, 1 day 18 hours ago

Capital increase through exercise of subscription rights
Published on 12/20/2024 at 17:55, 1 day 18 hours ago

Déclaration des transactions sur actions propres réalisées du 16/12/2024 au 20/12/2024

View all LES ECHOS COMFI WIRE

News